Aprea Therapeutics logo

Aprea TherapeuticsNASDAQ: APRE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

03 October 2019

Website:

http://atrinpharma.com

Next earnings report:

09 August 2024

Last dividends:

N/A

Next dividends:

N/A

Market cap

$20.09 M
-83%vs. 3y high
24%vs. sector

PE ratio

-
-vs. 3y high
-vs. sector

PB ratio

0.69
-69%vs. 3y high
33%vs. sector

PS ratio

-
-vs. 3y high
-vs. sector

Price

regular market | 9 min ago
$3.70-$0.10(-2.63%)

Dividend

No data over the past 3 years

EPS diluted

EPS diluted target

-$0.67-$0.63

Revenue

Revenue target

$70.00 K$50.00 K

Revenue

Net income

--$2.81 M

Analysts recommendations

Total assets

Total liabilities

$33.20 M$4.28 M

Institutional Ownership

Included in screeners

Small cap companies
Worst performing stocks today
Stocks with low RSI 14
Stocks with price below SMA 200
Stocks with low beta
Price lower than analysts target
Analysts recommendations: buy
Growing shares outstanding

Similar companies

Oncternal Therapeutics logo

Oncternal Therapeutics (ONCT)

Cumberland Pharmaceuticals logo

Cumberland Pharmaceuticals (CPIX)

Singular Genomics Systems logo

Singular Genomics Systems (OMIC)

NanoViricides logo

NanoViricides (NNVC)

Indaptus Therapeutics logo

Indaptus Therapeutics (INDP)

Aesthetic Medical International Holdings Group Limited logo

Aesthetic Medical International Holdings Group Limited (AIH)

American Shared Hospital Services logo

American Shared Hospital Services (AMS)

ATI Physical Therapy logo

ATI Physical Therapy (ATIP)

APRE Latest News

Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now
Zacks Investment Research24 April 2023 Sentiment: POSITIVE

Aprea Therapeutics, Inc. (APRE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

What type of business is Aprea Therapeutics?

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-cancer drugs that reactivate the mutant tumor suppressor protein p53. Its lead candidate product, APR-246, is a low molecular weight reactivator of p53 that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The company was founded in 2006 and is headquartered in Boston, Massachusetts.

What sector is Aprea Therapeutics in?

Aprea Therapeutics is in the Healthcare sector

What industry is Aprea Therapeutics in?

Aprea Therapeutics is in the Biotechnology industry

What country is Aprea Therapeutics from?

Aprea Therapeutics is headquartered in United States

When did Aprea Therapeutics go public?

Aprea Therapeutics initial public offering (IPO) was on 03 October 2019

What is Aprea Therapeutics website?

https://atrinpharma.com

Is Aprea Therapeutics in the S&P 500?

No, Aprea Therapeutics is not included in the S&P 500 index

Is Aprea Therapeutics in the NASDAQ 100?

No, Aprea Therapeutics is not included in the NASDAQ 100 index

Is Aprea Therapeutics in the Dow Jones?

No, Aprea Therapeutics is not included in the Dow Jones index

When does Aprea Therapeutics report earnings?

The next expected earnings date for Aprea Therapeutics is 09 August 2024